Actively Recruiting
Comparison of Immune Responses to Standard, MF59 Adjuvanted, and High Dose Influenza Vaccines in Older Adults with Repeated Annual Vaccination
Led by Korea University Guro Hospital · Updated on 2026-09-24
180
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating how different influenza vaccine formulations affect immune responses in older adults, especially considering immune aging and the effects of repeated annual vaccination. The study focuses on adults aged 65 years or older receiving standard dose, MF59 adjuvanted, or high dose influenza vaccines, with younger adults aged 19 to 49 years receiving standard dose vaccine as a reference group to compare age-related immune differences. Participants will receive a single intramuscular dose of one of the influenza vaccines according to the approved prescribing information. The study involves three vaccine types for older adults standard dose, MF59 adjuvanted, and high dose. Younger adults will receive the standard dose vaccine. This is a randomized study comparing immune responses across these groups, with follow-up occurring annually for up to three years. During the study, participants will provide blood samples before and after vaccination to measure antibody levels and other immune responses. Some may also provide nasal samples for detailed immune evaluation. Researchers will assess geometric mean titers and fold rises of hemagglutination inhibition antibodies one month after vaccination each year, along with other immune markers such as seroconversion, B cell and T cell frequencies, and nasal secretory IgA. The study lasts up to three years with annual vaccinations and assessments.
CONDITIONS
Brief Title
Influenza Vaccine Immunogenicity in Repeatedly Vaccinated Older Adults
Research Team
M
Min Joo Choi, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here